Last reviewed 2026-04-19 · How we verify

FLOMOXEF

FLOMOXEF works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

FLOMOXEF is a small molecule antibiotic belonging to the flomoxef class. It is used to treat bacterial infections, although its specific indications are unknown. The commercial status of FLOMOXEF is unclear, as it is not stated whether it is patented or generic. Its half-life is approximately 0.6 hours, which may require frequent dosing. Further information on its approval status, bioavailability, and generic manufacturers is not available.

At a glance

Mechanism of action

Imagine the bacterial cell wall as a brick wall. FLOMOXEF blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse. This prevents the bacteria from growing and multiplying, ultimately leading to the death of the bacterial cell.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• FLOMOXEF CI brief — competitive landscape report
• FLOMOXEF updates RSS · CI watch RSS